📊 CELZ Key Takeaways
Is Creative Medical Technology Holdings, Inc.. (CELZ) a Good Investment?
CELZ is a pre-revenue or near-zero revenue biotech company with severe operational losses and negative cash burn, losing $5.9M in operating cash flow against only $6K in annual revenue. Despite maintaining adequate liquidity ($7.2M cash), the company is burning capital at an unsustainable rate with no demonstrated path to profitability or revenue generation. The biological products company shows no evidence of commercial traction or viable product portfolio.
Creative Medical Technology Holdings shows essentially no operating scale, with just $6K of revenue against more than $6M of operating losses and negative operating cash flow of $5.86M. While the balance sheet appears liquid due to $7.21M of cash and low reported liabilities, the business currently lacks revenue traction and is consuming cash at a pace that raises major concerns about sustainability and growth quality.
Why Buy Creative Medical Technology Holdings, Inc.. Stock? CELZ Key Strengths
- Strong liquidity position with $7.2M cash and 25.97x current ratio provides near-term runway
- Reasonable debt/equity ratio of 0.68x limits financial leverage risk
- Gross margin of 63.4% on limited revenue suggests potential unit economics if scaled
- Large cash balance relative to reported near-term obligations supports short-term liquidity
- Very high current and quick ratios indicate no immediate working-capital stress
- Low absolute liabilities versus assets suggests some balance-sheet flexibility if data is accurate
CELZ Stock Risks: Creative Medical Technology Holdings, Inc.. Investment Risks
- Catastrophic revenue collapse of 45.5% YoY to only $6K indicates complete loss of commercial viability
- Operating cash burn of $5.9M annually against minimal revenue is unsustainable; at current burn rate, cash exhaustion within 14 months
- Massive operating losses of $6.1M (-102,380% margin) with no clear path to profitability or commercialization
- Zero insider purchases in last 90 days signals lack of management confidence
- Biological products company with no revenue suggests failed product pipeline or market rejection
- Revenue base is negligible and declined 45.5% year over year, indicating weak commercial execution
- Operating and free cash flow losses are severe, implying continued dependence on external financing or capital depletion
- Reported balance-sheet figures appear internally inconsistent because long-term debt exceeds total liabilities, increasing uncertainty around data quality and true leverage
Key Metrics to Watch
- Quarterly revenue trend and any new product commercialization announcements
- Monthly cash burn rate and projected runway until capital depletion
- Operating cash flow trajectory and achievement of cash flow positive operations
- Any clinical trial progress, regulatory approvals, or partnership announcements for revenue-generating products
- Quarterly revenue growth and evidence of commercial scale-up
- Cash burn relative to cash balance, including operating cash flow and financing needs
Creative Medical Technology Holdings, Inc.. (CELZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 25.97x current ratio provides a solid financial cushion.
CELZ Profit Margin, ROE & Profitability Analysis
CELZ vs Healthcare Sector: How Creative Medical Technology Holdings, Inc.. Compares
How Creative Medical Technology Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Creative Medical Technology Holdings, Inc.. Stock Overvalued? CELZ Valuation Analysis 2026
Based on fundamental analysis, Creative Medical Technology Holdings, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Creative Medical Technology Holdings, Inc.. Balance Sheet: CELZ Debt, Cash & Liquidity
CELZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Creative Medical Technology Holdings, Inc..'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-3.71 indicates the company is currently unprofitable.
CELZ Revenue Growth, EPS Growth & YoY Performance
CELZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.0M | $-0.48 |
| Q2 2025 | N/A | -$1.2M | $-0.48 |
| Q1 2025 | N/A | -$1.0M | $0.73 |
| Q3 2024 | N/A | -$1.0M | N/A |
| Q2 2024 | N/A | -$1.1M | N/A |
| Q1 2024 | N/A | -$1.0M | N/A |
| Q3 2023 | $6.0K | -$982.3K | N/A |
| Q2 2023 | N/A | -$1.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Creative Medical Technology Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CELZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Creative Medical Technology Holdings, Inc.. (CIK: 0001187953)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CELZ
What is the AI rating for CELZ?
Creative Medical Technology Holdings, Inc.. (CELZ) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELZ's key strengths?
Claude: Strong liquidity position with $7.2M cash and 25.97x current ratio provides near-term runway. Reasonable debt/equity ratio of 0.68x limits financial leverage risk. ChatGPT: Large cash balance relative to reported near-term obligations supports short-term liquidity. Very high current and quick ratios indicate no immediate working-capital stress.
What are the risks of investing in CELZ?
Claude: Catastrophic revenue collapse of 45.5% YoY to only $6K indicates complete loss of commercial viability. Operating cash burn of $5.9M annually against minimal revenue is unsustainable; at current burn rate, cash exhaustion within 14 months. ChatGPT: Revenue base is negligible and declined 45.5% year over year, indicating weak commercial execution. Operating and free cash flow losses are severe, implying continued dependence on external financing or capital depletion.
What is CELZ's revenue and growth?
Creative Medical Technology Holdings, Inc.. reported revenue of $6.0K.
Does CELZ pay dividends?
Creative Medical Technology Holdings, Inc.. does not currently pay dividends.
Where can I find CELZ SEC filings?
Official SEC filings for Creative Medical Technology Holdings, Inc.. (CIK: 0001187953) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELZ's EPS?
Creative Medical Technology Holdings, Inc.. has a diluted EPS of $-2.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CELZ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Creative Medical Technology Holdings, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CELZ stock overvalued or undervalued?
Valuation metrics for CELZ: ROE of -79.8% (sector avg: 15%), net margin of -99,916.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CELZ stock in 2026?
Our dual AI analysis gives Creative Medical Technology Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CELZ's free cash flow?
Creative Medical Technology Holdings, Inc..'s operating cash flow is $-5.9M, with capital expenditures of N/A. FCF margin is -97,607.4%.
How does CELZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -99,916.8% (avg: 12%), ROE -79.8% (avg: 15%), current ratio 25.97 (avg: 2).